%0 Journal Article %A Spelman, L M. %A Walsh, P I. %A Sharifi, N %A Collins, Patrick B. %A Thakore, J H. %D 2019 %T Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. %U https://repository.rcsi.com/articles/journal_contribution/Impaired_glucose_tolerance_in_first-episode_drug-na_ve_patients_with_schizophrenia_/10783691 %2 https://repository.rcsi.com/ndownloader/files/19296956 %K Adult %K Blood Glucose %K Cross-Sectional Studies %K Female %K Glucose Intolerance %K Glucose Tolerance Test %K Humans %K Male %K Middle Aged %K Schizophrenia %K Clinical Pharmacology and Therapeutics %X AIMS: To determine whether there is an association between Type 2 diabetes mellitus and schizophrenia, independent of medication. METHODS: In this cross-sectional study we performed an oral glucose tolerance test on 38 non-obese white Caucasians who fulfilled the criteria for first-episode drug-naïve schizophrenia, 38 control subjects (matched for age, gender, smoking status, alcohol intake and ethnicity) and 44 first-degree relatives of the patients. RESULTS: The frequency of impaired glucose tolerance (IGT), defined by World Health Organization criteria, was 10.5% (n = 4) in patients with schizophrenia, 18.2% (n = 8) in unaffected relatives and 0.0% in healthy control subjects (chi(2) = 4.22, d.f. = 2, P < 0.05). CONCLUSIONS: The high point prevalence of IGT in never-treated patients and relatives supports either shared environmental or genetic predisposition to IGT. Both patients and their relatives present an ideal cost-effective opportunity to screen for Type 2 diabetes mellitus, as they are both easily identifiable. %I Royal College of Surgeons in Ireland